A vaccine regimen intended to prevent chronic HCV infection was tested in a double-blind placebo-controlled trial. It failed. The incidence of chronic HCV infection was the same in the vaccinated group as in the placebo group.
Our ability to develop new drugs is fast outstripping our ability to pay for them; some are exorbitantly expensive and not very effective. Funds are limited, and as a society we need to have a serious discussion about how they are to be allocated.